We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bend Research Signs License Agreement with Eli Lilly And Company
News

Bend Research Signs License Agreement with Eli Lilly And Company

Bend Research Signs License Agreement with Eli Lilly And Company
News

Bend Research Signs License Agreement with Eli Lilly And Company

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bend Research Signs License Agreement with Eli Lilly And Company"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bend Research Inc. has announced that it has entered into a licensing agreement with Eli Lilly and Company.

Under the terms of the agreement, Bend Research will make its proprietary spray-dried dispersion (SDD) technology available to Lilly.

This technology, which improves the bioavailability of compounds with low aqueous solubility, has been applied successfully to hundreds of compounds at various stages of development, from preclinical studies to Phase III clinical trials.

Lilly formulators and scientists will also have broad access to Bend Research’s portfolio of other drug-delivery technologies.

In addition, as part of an already existing agreement with Lilly, Bend Research will continue to provide formulation, development, analytical, engineering and manufacturing services to Lilly to support its preclinical and clinical development programs.

“This expansion in our relationship with Lilly is a great milestone for us,” said Rod Ray, Chief Executive Officer of Bend Research.

Ray continued, “Our teams work well together and have a shared commitment to bring the best new medicines to caregivers and patients. We believe this collaboration will add significant value to Lilly’s research efforts and help them advance their compounds more quickly and efficiently.”

Advertisement